Articles tagged with Ovarian Cancer
Dr. Nita Maihle is leading a national DOD initiative to support early career ovarian cancer investigators. The program aims to foster team science and improve understanding of the disease. With a focus on secretory cells that line the fallopian tubes, researchers hope to develop targeted therapies for this deadly form of cancer.
A new study published in Cell Reports identifies microRNA molecule miR551b as a promising candidate biomarker and therapeutic target for treating ovarian cancers. The research found that targeting miR551b expression could block STAT3 activity, offering potential for treating the most common and deadly form of ovarian cancer.
A new study by researchers at the University of Pennsylvania's Abramson Cancer Center found that testing non-breast cancer genes in high-risk women does not add clinical benefit. The study analyzed a large panel of genes and found that many variants were of uncertain significance, adding complexity to genetic counseling.
A study of 36 women found nearly all carried cancer-associated gene mutations, suggesting high accuracy and sensitivity for detecting ovarian cancer. Duplex sequencing technology can identify low-frequency cancer-like mutations, potentially leading to early detection and treatment.
A study published in Human Reproduction found that women with BRCA1 gene mutations have lower levels of anti-Müllerian hormone, indicating reduced ovarian reserves. This may impact fertility and suggest a need for earlier pregnancy planning.
A Phase 1/2 clinical trial is being conducted to evaluate the combination of MedImmune's durvalumab and VentiRx's motolimod in locally advanced or recurrent ovarian cancers. The study aims to assess the safety and efficacy of the combination, with a focus on enhancing anti-tumor immune responses.
Researchers have discovered a molecular fingerprint of some deadly cancers, including a genomic configuration called the tandem duplicator phenotype (TDP) that is enriched in triple-negative breast cancer and other types. This TDP is sensitive to cisplatin chemotherapy and can be scored using a genome-based formula.
A study presented at the 2016 USCAP Conference found that HER4 expression is associated with chemotherapy resistance and a lower survival rate in ovarian serous cancer patients. The research, led by Moffitt Cancer Center pathologists, suggests that HER4 may be a prognostic and potentially predictive marker for this type of cancer.
Researchers discover small peptides psaptides that can force tumors to regress by stimulating an anti-angiogenic response in healthy tissues. Psaptides mimic the naturally occurring human protein prosaposin, which stimulates immune cells to produce a potent anti-inflammatory protein called thrombospondin-1.
A multicentre study found type 1 diabetes associated with higher cancer incidence, especially for cancers of the stomach, liver, pancreas, endometrium, ovary, and kidney. Women with type 1 diabetes had a smaller but still significant increased risk compared to men.
Researchers at St. Joseph's Hospital and Medical Center found that a standard front-line treatment for advanced ovarian cancer should involve every three week chemotherapy with carboplatin, paclitaxel plus bevacizumab, or weekly dose intense paclitaxel without bevacizumab
A study at The Wistar Institute revealed that Satb1 expression is required for proper immune response, but its prolonged presence drives immunosuppressive behavior. Silencing Satb1 in tumor-associated dendritic cells boosted T-cell activation and reduced inflammation.
The Independent Data Monitoring Committee has recommended continuing the Phase III trial with PM1183 due to positive safety data from the first 80 patients. The trial assesses PM1183's efficacy compared to standard treatments for platinum-resistant ovarian cancer.
Researchers argue for greater support and research to help women make informed decisions about preventive mastectomies and ovary removal. The procedures can significantly reduce cancer risk but also carry risks and emotional challenges.
A study by Yale University researchers found that very few women undergo bilateral salpingectomy with ovarian conservation during hysterectomies for non-cancerous conditions. The procedure may help protect against ovarian cancer and preserve hormonal levels, but its use varies widely among hospitals across the US.
A new treatment model recommends aggressive surgery followed by targeted chemotherapy to achieve a 50% cure rate for women with advanced-stage ovarian cancer. This approach differs from current conventional treatments, which often result in a 20% survival rate.
A new algorithm assesses adnexal masses with ultrasound, identifying 89-99% of patients with ovarian cancer. The approach allows for individualized patient management and potentially levels the playing field in expert interpretation.
A study published in the Journal of the National Cancer Institute found that women carrying an inherited BRIP1 gene fault are over three times more likely to develop ovarian cancer. The research also showed that these women tend to be diagnosed with aggressive cancers at a later age and have a higher risk of dying from the disease.
Researchers found that auranofin reduces the survival rates of ovarian cancer cells with depleted BRCA1 levels, increasing their sensitivity to the drug. This suggests auranofin's potential as a clinical treatment for ovarian cancers with BRCA1 deficiency.
A study of 200,000 twin individuals found an increased cancer risk among those whose co-twin was diagnosed with cancer. The risks varied by type and were higher for monozygotic twins.
A new study published in The Lancet found that annual blood tests for ovarian cancer screening may reduce mortality rates by up to 20%. The UK Collaborative Trial of Ovarian Cancer Screening showed a delayed effect on mortality between the screening and control arms, becoming significant after seven years.
A 14-year study found that annual screening with a blood test utilizing the Risk of Ovarian Cancer Algorithm (ROCA) significantly reduced mortality from ovarian cancer, particularly in women without evidence of cancer at study entry. The results showed a 20% reduction in risk of dying from ovarian cancer.
The UKCTOCS trial found that ovarian cancer screening reduced mortality by an estimated 15-28% in the MMS group compared to no screening. Longer follow-up is needed to confirm these results and determine their cost-effectiveness.
Researchers have developed fallopian tube organoids to study female genital diseases such as infertility, inflammatory disease, and ovarian cancer. These hollow spheres can culture cells from clinical fallopian tube samples, offering a new avenue for investigating disease mechanisms and developing therapies.
A recent study published in Cancer Research reveals that obesity contributes to metastasis in ovarian cancer patients. Researchers from the University of Notre Dame found that tumor cells are better able to metastasize when grown in a high-fat environment, suggesting potential targets for dietary and therapeutic interventions.
Researchers at Kyoto University have discovered that an antibody called nivolumab may help patients with platinum-resistant ovarian cancer heal themselves by targeting the PD-1 signal. A phase II clinical trial found that most patients treated with nivolumab experienced a median overall survival of 20 months.
Hui Shen, a Van Andel Research Institute Assistant Professor, has received an Ovarian Cancer Research Fund award to investigate cell types that may be used to pinpoint ovarian cancer's cells of origin. Her research aims to identify epigenetic fingerprints of specific genomic regions of ovarian cancer cells and normal cells.
Researchers at Georgia Institute of Technology have identified 16 metabolite compounds that provide high accuracy in distinguishing early-stage ovarian cancer from healthy women. The study uses advanced liquid chromatography and mass spectrometry techniques coupled with machine learning algorithms.
Researchers at UCLA have found a new way to reduce painful ascites, a common condition in ovarian cancer patients. The experimental drug inhibits macrophages, immune cells that help cancer spread, making the abdominal cavity less conducive to tumor growth.
African-American women with a healthier diet, based on the Alternate Healthy Eating Index-2010 (AHEI-2010), were 34% less likely to be diagnosed with ovarian cancer. The study found that higher vegetable intake and lower intake of empty calories contributed to the reduced risk.
A study by Mayo Clinic researchers found that women with a history of oral contraceptive use have improved progression-free survival and overall survival rates compared to those who did not use the pill. The study suggests that oral contraceptives may reduce DNA mutations, leading to less aggressive ovarian cancer at a later date.
A recent study published in International Journal of Gynecological Cancer found that protein CK5 marks ovarian cancers likely to be resistant to cisplatin. This marker could help predict and analyze platinum resistance, potentially improving treatment outcomes.
Researchers found that cancer cells hijack glucose to alter immune cells, leading to reduced T cell effectiveness. However, they also discovered a potential metabolic pathway to make T cells resistant to glucose restriction, which could improve cancer treatment outcomes.
Studies show that having one child reduces the risk of certain types of ovarian cancer, such as serous, mucinous, endometrioid, and clear cell tumours. Women who have had their fallopian tubes cut or clipped also experience a lower risk of developing these cancers.
Research on biodegradable nanomedicine shows promise in selectively destroying ovarian cancer cells left behind after surgery. The technology uses nanoparticles to provide real-time imaging and phototherapy treatment during surgery, achieving complete tumor eradication in mice with no adverse effects.
Researchers at the University of Georgia have discovered a mechanism that could lead to better ovarian cancer treatment by targeting chemoresistance. The RGS10 protein impacts the effectiveness of chemotherapy, and manipulating its expression can improve treatment outcomes.
PharmaMar presents new studies on the treatment of ovarian cancer using YONDELIS (trabectedin) and PM1183, showing promising results in managing recurrent cancer. The studies highlight the potential benefits of combining these therapies to improve patient outcomes.
Researchers found that mice with BRCA1 mutations exhibited enhanced responsiveness to male scent, which stimulated their estrous cycles and ovary function. This discovery suggests a potential indirect link between sense of smell and breast, ovarian cancer risk in women carrying BRCA1 mutations.
A Binghamton University biochemist has discovered a method to fight cancer by attacking only cancer cells and potentially reducing side effects. Hedgehogs, which normally turn off in mature cells, somehow re-activate in certain cancers, leading to uncontrolled cell growth.
A study of 41 Danish women who received ovarian tissue transplants found that the procedure is effective in restoring ovarian function and fertility in up to 10 years. The majority of patients (31%) became pregnant, with some even experiencing full-term pregnancies.
A study of commercially insured women found that most did not receive genetic counseling after BRCA testing, with lack of clinician recommendation being the main reason. Women who received counseling had greater knowledge and satisfaction with their test results.
Researchers developed a small array of flexible sensors to analyze breath samples for specific compounds indicative of ovarian cancer. The system showed an 82% accuracy rate in detecting these compounds, paving the way for a potential less invasive cancer diagnosis method.
A major clinical trial reports that hormone replacement therapy (HRT) is safe and may improve survival chances in women with epithelial ovarian cancer. The study followed 150 women with the common type of ovarian cancer and found that HRT did not reduce overall survival, but rather increased it.
Researchers found that adding hormonal treatment during chemotherapy reduced the risk of premature ovarian failure by 45% and increased pregnancy rates among young breast cancer patients. The use of LHRHa could be a potential standard strategy to preserve ovarian function and fertility in hormone receptor positive breast cancers.
Researchers at NC State University isolated possible ovarian cancer biomarkers using a highly sensitive mass spectrometry analysis. The study found that the level of biomarkers associated with ovarian cancer does not simply increase or decrease over the course of the disease, but can rise and fall during different stages.
Two studies suggest alternative prevention strategies may render surgery unnecessary for women at high risk of breast and ovarian cancer. Researchers identify a new target to decrease breast cancer risk by blocking the effects of RANKL with OPG.
Researchers found that generic heart medications, specifically nonselective beta-blockers, significantly improved overall survival among ovarian cancer patients. This is attributed to the ability of these drugs to block stress pathways involved in tumor growth and spread, with further research needed to explore their potential benefits.
A study found that multigene panel testing identified harmful mutations in moderate-risk genes and Lynch syndrome genes among 3.8% of women negative for BRCA1 and BRCA2 mutations. The test also recommended additional disease-specific screening and prevention measures for mutation-positive cases.
A study found that screening women with suspected hereditary breast or ovarian cancer risk for additional genes provides important information for changing clinical management. Most patients with identified mutations were recommended for enhanced screening or preventive measures, and close relatives should also be screened.
The University of South Florida (USF) and the cancer advocacy organization FORCE will advance a clinical research network focused on hereditary breast and ovarian cancer. The project aims to improve health outcomes for patients by leveraging large volumes of health data, enabling quicker and less expensive clinical research.
A UC Davis study found that nearly one-third of ovarian cancer patients survived at least 10 years after diagnosis, contradicting the common perception of poor survival rates. The research also identified younger, earlier-stage disease and lower-risk tumor types as factors associated with longer survival.
Researchers discovered that CA125-negative tumor cells have an enhanced ability to repair their DNA and resist programmed cell death, making them dangerous. Combining chemotherapy with birinapant significantly improved disease-free survival in laboratory models of human ovarian cancer.
A modified version of a protein that suppresses female reproductive organ development has been shown to inhibit the growth of chemotherapy-resistant ovarian tumors in animal models. Researchers at Massachusetts General Hospital have developed a gene therapy approach using a viral vector to deliver this protein, which resulted in signif...
Researchers at Lawson Health Research Institute have identified LKB1 as a key player in promoting and surviving ovarian cancer cells. This discovery contradicts previous studies, which suggested that LKB1 acts as a tumour suppressor in ovarian cancer.
Researchers have uncovered how key proteins can switch on RAD51, allowing it to repair cancer-causing DNA damage in cells. Women with faulty RAD51 and BRCA1 and BRCA2 genes are at higher risk of developing these cancers.
A new study found that longer periods of leisure time sitting were associated with a higher risk of total cancer risk in women, as well as increased risk of multiple myeloma, invasive breast cancer, and ovarian cancer. The association was not observed in men.
Researchers at Johns Hopkins have found that combining fostamatinib with paclitaxel can reduce tumor size in ovarian cancer cells by up to 87 percent. The combination therapy may provide a new treatment option for patients with recurrent advanced ovarian cancer who have developed resistance to standard treatments.
An international genome-wide association study (GWAS) has identified three genetic variants associated with mucinous ovarian carcinomas (MOCs), offering insights into the biology of this disease. The research also highlights the link between MOCs and colorectal cancer, as well as the discovery of a key gene called HOXD9.
Ovarian cancer suppresses immune cells' ability to respond to tumor cells by activating a gene called XBP1. A novel therapy approach aims to restore dendritic cell function and trigger robust immune responses against ovarian tumors.
A recent study reveals that nearly 1 in 3 counties in the US have limited access to specialty care for ovarian and cervical cancers, affecting 14.8 million women. The study also found that 15% of women may face barriers to care due to their referral network.